skip to content
Primary navigation


Drug - Farydak® (panobinostat) [Genentech, Inc.]

May 2016

Therapeutic area - Oncology

Approval criteria

  • Patient must be 18 years of age or older AND
  • Have a diagnosis of multiple myeloma AND
  • Will be used in conjunction with bortezomib and dexamethasone AND
  • Has received at least 2 prior chemotherapy regimens, including bortezomib and an immunomodulatory agent

Quantity limit

Maximum of 6 capsules per 21 days


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top